Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Advances in advanced metastatic renal cell carcinoma from ESMO 2012

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.12
Views: 6699

Dr Robert Motzer - The Memorial Sloan-Kettering Cancer Center, USA

Dr Robert Motzer from the Memorial Sloan-Kettering Cancer Center in the USA talks to ecancer TV about recent advances in the first-line setting in metastatic renal cell carcinoma (mRCC).


Dr Motzer first outlines the history of renal cell carcinoma advances in first-line therapy, and then reviews the latest data comparing pazopanib and sunitinib in 1,110 treatment-naïve patients with clear cell mRCC and measurable disease.  He outlines the observed differences in the side effect profiles of these two agents, and outlines the quality of life study comparing these agents.


Dr Motzer emphasises the value of all treatment choices that now exist for individual patients in clinical practice, and outlines the potential role of experimental treatments.  He notes the importance of on-going clinical studies, including the PROTECT trial with pazopanib in the adjuvant setting in 1,500 patients with localised RCC.


This programme has been supported by an educational grant from GlaxoSmithKline.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation